Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
about
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyMolecular response prediction in CML: novel ideas?Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment.Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
P2860
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tyrosine kinase inhibitors as ...... A mixed-treatment comparison.
@en
type
label
Tyrosine kinase inhibitors as ...... A mixed-treatment comparison.
@en
prefLabel
Tyrosine kinase inhibitors as ...... A mixed-treatment comparison.
@en
P2093
P2860
P356
P1476
Tyrosine kinase inhibitors as ...... : A mixed-treatment comparison
@en
P2093
Ahmad Zarzour
Archana Garipalli
Aref Al-Kali
Belal Firwana
Donald Doll
Ibrahim Yousef
M Hassan Murad
Maria Diab
Shahzad Raza
P2860
P304
P356
10.1002/IJC.29889
P577
2015-10-28T00:00:00Z